Henkhaus Rebecca S, Kim Soo-Jeong, Kimonis Virginia E, Gold June-Anne, Dykens Elisabeth M, Driscoll Daniel J, Butler Merlin G
Department of Psychiatry and Behavioral Sciences and Pediatrics, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
Genet Test Mol Biomarkers. 2012 Mar;16(3):178-86. doi: 10.1089/gtmb.2011.0115. Epub 2011 Oct 6.
Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are complex neurodevelopmental disorders caused by loss of expression of imprinted genes from the 15q11-q13 region depending on the parent of origin. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) kits from MRC-Holland (Amsterdam, The Netherlands) were used to detect PWS and AS deletion subtypes. We report our experience with two versions of the MS-MLPA-PWS/AS kit (original A1 and newer B1) in determining methylation status and deletion subtypes in individuals with PWS.
MS-MLPA analysis was performed on DNA isolated from a large cohort of PWS subjects with the MS-MLPA-PWS/AS-A1 and -B1 probe sets.
Both MS-MLPA kits will identify deletions in the 15q11-q13 region but the original MS-MLPA-A1 kit has a higher density of probes at the telomeric end of the 15q11-q13 region, which is more useful for identifying individuals with atypical deletions. The newer B1 kit contains more probes in the imprinting center (IC) and adjoining small noncoding RNAs useful in identifying small microdeletions.
The A1 kit identified the typical deletions and smaller atypical deletions, whereas the B1 kit was more informative for identifying microdeletions including the IC and SNORD116 regions. Both kits should be made available for accurate characterization of PWS/AS deletion subtypes as well as evaluating for IC and SNORD116 microdeletions.
普拉德-威利综合征(PWS)和安吉尔曼综合征(AS)是复杂的神经发育障碍,由15q11-q13区域印记基因的亲本来源依赖性表达缺失引起。使用来自荷兰阿姆斯特丹MRC-Holland公司的甲基化特异性多重连接依赖探针扩增(MS-MLPA)试剂盒检测PWS和AS缺失亚型。我们报告了我们使用两种版本的MS-MLPA-PWS/AS试剂盒(原始的A1和更新的B1)来确定PWS个体甲基化状态和缺失亚型的经验。
使用MS-MLPA-PWS/AS-A1和-B1探针组对从大量PWS受试者中分离的DNA进行MS-MLPA分析。
两种MS-MLPA试剂盒均可识别15q11-q13区域的缺失,但原始的MS-MLPA-A1试剂盒在15q11-q13区域的端粒末端具有更高密度的探针,这对于识别非典型缺失个体更有用。更新的B1试剂盒在印记中心(IC)和相邻的小非编码RNA中包含更多探针,有助于识别小的微缺失。
A1试剂盒可识别典型缺失和较小的非典型缺失,而B1试剂盒在识别包括IC和SNORD116区域的微缺失方面提供的信息更多。两种试剂盒都应提供,以准确表征PWS/AS缺失亚型以及评估IC和SNORD116微缺失。